Trial Profile
A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2023
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Adverse reactions; Registrational
- Acronyms Rising Up
- Sponsors AbbVie
- 12 Dec 2023 Results assessing long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with atopic dermatitis, published in the Dermatology and Therapy.
- 25 Jun 2023 Results of a post-hoc analysis assessing acne events in Japanese patients with AD who received upadacitinib published in the Dermatology and Therapy
- 19 Nov 2022 Interim Results(n=242; 2 year interim results through 112 weeks:data cutoff date:11 August 2021) assessing Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan published in the Dermatology and Therapy